🔒 Rev Up: Geno.Me focuses on rising consumer base as firm nears shut of seed two spherical

Milwaukee-based biotech startup Geno.Me is concentrated on increasing its consumer base and boosting gross sales because it nears the shut of its seed II funding spherical, which has a cap of greater than $3 million.

Geno.Me hyperlinks genomic and digital well being file knowledge in an open market, which permits medical researchers to extra simply entry knowledge and sufferers to have extra transparency and management of the usage of their private well being and medical knowledge, based on Britt Gottschalk, the corporate’s founder and chief government officer. Sufferers who share their knowledge are compensated. 

Gottschalk has expertise as a administration marketing consultant. She based Geno.Me throughout the COVID-19 pandemic after she recognized inefficiencies associated to affected person knowledge switch and accessibility within the American well being care system.

“The entire thought behind Geno.Me is to mainly give individuals energy again over their knowledge,” stated Gottschalk. “You haven’t all the time had the flexibility to have this a lot management over your knowledge as you might need perceived.”

The corporate not solely needs customers to have management over their well being knowledge, but additionally to place that knowledge to good use. Geno.Me will help customers higher perceive how their inherited and environmental well being care traits might have an effect on them.

“There’s not a ton of analysis being executed based mostly on the viability of a medical file in tandem with a genetic report,” stated Gottschalk. “The medical file and genetic report inform very completely different sides of your well being story.”

She defined the problem will not be essentially getting access to medical information however having a lot medical info in a mess of locations that makes it tough for individuals to take management over their very own knowledge. 

“Let’s say you progress to Arizona, and now there’s just one hospital community. With the ability to get your medical knowledge reported precisely into that new system is mostly a problem as a result of these methods lots of occasions don’t speak to one another,” stated Gottschalk. 

Milwaukee-based Gateway Capital was the lead investor in Geno.Me’s $500,000 seed spherical in 2021. Two angel buyers offered $50,000 every whereas Gateway Capital invested $400,000. Final April, Geno.Me launched its seed II spherical with a purpose of $3.25 million. As of Feb. 1, the corporate had secured $2.5 million.

The extra funding will permit Geno.Me so as to add some extra key workers. The corporate named Shawn Belling as its first chief know-how officer in December. There will even be additions to the corporate’s product improvement group. 

The Geno.Me platform formally launched final October with greater than 40 lively customers. The corporate has been working with researchers from the Medical Faculty of Wisconsin to flesh out the platform’s options. Finally, customers may have new skills together with having the ability to see what group has accessed their knowledge and for what objective. 

“With the ability to actually put our heads down and concentrate on working with the businesses that want our companies and actually rising the gross sales aspect and consumer base is entrance of thoughts for me,” stated Gottschalk. “During the last yr, we went from having no platform to having an operational platform, and now we simply wish to get on the market and present firms that is one thing that may be actually useful to your researchers, workers and sufferers.”

Management: Britt Gottschalk, founder and CEO
Headquarters: Milwaukee
What it does: Hyperlinks genomic and digital well being file knowledge in an open market
Based: 2020
Workers: 8
Subsequent Objectives: Increasing consumer base, boosting gross sales
Funding: $3 million